Carolina Gonzaga Carvalho

Dr. Carolina Gonzaga Carvalho

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Hypertension
Verified
Journal Article
Open access
PDF file
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
LDLuciano F. Drager
Luciano F. Drager
CCCarolina Gonzaga Carvalho
Carolina Gonzaga Carvalho
MSMarcio G. Sousa
Marcio G. Sousa
LPLílian K.G. de Paula
Lílian K.G. de Paula
GLGeraldo Lorenzi-Filho
Geraldo Lorenzi-Filho
Recognition and treatment of secondary causes of hypertension among patients with resistant hypertension may help to control blood pressure and reduce cardiovascular risk. However, there are no studies systematically evaluating secondary causes of hypertension according to the Seventh Joint National Committee. Consecutive patients with resistant hypertension were investigated for known causes of hypertension irrespective of symptoms and signs, including aortic coarctation, Cushing syndrome, obstructive sleep apnea, drugs, pheochromocytoma, primary aldosteronism, renal parenchymal disease, renovascular hypertension, and thyroid disorders. Among 125 patients (age: 52±1 years, 43% males, systolic and diastolic blood pressure: 176±31 and 107±19 mm Hg, respectively), obstructive sleep apnea (apnea-hypopnea index: >15 events per hour) was the most common condition associated with resistant hypertension (64.0%), followed by primary aldosteronism (5.6%), renal artery stenosis (2.4%), renal parenchymal disease (1.6%), oral contraceptives (1.6%), and thyroid disorders (0.8%). In 34.4%, no secondary cause of hypertension was identified (primary hypertension). Two concomitant secondary causes of hypertension were found in 6.4% of patients. Age >50 years (odds ratio: 5.2 [95% CI: 1.9–14.2]; P 50 years, large neck circumference measurement, and snoring are good predictors of obstructive sleep apnea in this population.

1 April 2010 in The American Journal of Cardiology
Verified
Journal Article
Closed access
LDLuciano F. Drager
Luciano F. Drager
PGPedro R. Genta
Pedro R. Genta
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
FNFlávia B. Nerbass
Flávia B. Nerbass
CCCarolina Gonzaga Carvalho
Carolina Gonzaga Carvalho
GLGeraldo Lorenzi-Filho
Geraldo Lorenzi-Filho

14 April 2020 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
KLKelly A Loffler
Kelly A Loffler
EHEmma Heeley
Emma Heeley
RFRuth Freed
Ruth Freed
RMRosie Meng
Rosie Meng
LBLia R. Bittencourt
Lia R. Bittencourt
LDLuciano F. Drager
Luciano F. Drager
OBJECTIVE Despite evidence of a relationship among obstructive sleep apnea (OSA), metabolic dysregulation, and diabetes, it is uncertain whether OSA treatment can improve metabolic parameters. We sought to determine effects of long-term continuous positive airway pressure (CPAP) treatment on glycemic control and diabetes risk in patients with cardiovascular disease (CVD) and OSA. RESEARCH DESIGN AND METHODS Blood, medical history, and personal data were collected in a substudy of 888 participants in the Sleep Apnea cardioVascular Endpoints (SAVE) trial in which patients with OSA and stable CVD were randomized to receive CPAP plus usual care, or usual care alone. Serum glucose and glycated hemoglobin A1c (HbA1c) were measured at baseline, 6 months, and 2 and 4 years and incident diabetes diagnoses recorded. RESULTS Median follow-up was 4.3 years. In those with preexisting diabetes (n = 274), there was no significant difference between the CPAP and usual care groups in serum glucose, HbA1c, or antidiabetic medications during follow-up. There were also no significant between-group differences in participants with prediabetes (n = 452) or new diagnoses of diabetes. Interaction testing suggested that women with diabetes did poorly in the usual care group, while their counterparts on CPAP therapy remained stable. CONCLUSIONS Among patients with established CVD and OSA, we found no evidence that CPAP therapy over several years affects glycemic control in those with diabetes or prediabetes or diabetes risk over standard-of-care treatment. The potential differential effect according to sex deserves further investigation.

1 December 2017 in Chest
Verified
Journal Article
Closed access
CUCarlos Henrique G. Uchôa
Carlos Henrique G. Uchôa
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
SJShahrokh Javaheri
Shahrokh Javaheri
GGGlaucylara R. Geovanini
Glaucylara R. Geovanini
MCMartinha M.B. Carvalho
Martinha M.B. Carvalho
LDLuciano F. Drager
Luciano F. Drager

23 November 2008 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
CCCarolina Gonzaga Carvalho
Carolina Gonzaga Carvalho
DCDavid A. Calhoun
David A. Calhoun

24 May 2018 in Journal of Human Hypertension
Verified
Journal Article
Closed access
PDF file
SGSara Q. C. Giampá
Sara Q. C. Giampá
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
CCCarolina Gonzaga Carvalho
Carolina Gonzaga Carvalho
ABAdriana Bertolami
Adriana Bertolami
CACelso Amodeo
Celso Amodeo
LDLuciano F. Drager
Luciano F. Drager